CLINICAL TRIALS PROFILE FOR GADOBUTROL
✉ Email this page to a colleague
505(b)(2) Clinical Trials for gadobutrol
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Dosage | NCT03602339 ↗ | Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose | Completed | Bayer | Phase 4 | 2018-11-14 | The study was conducted to gain knowledge about a new dose of a diagnostic drug that is used for contrast-enhanced Magnetic Resonance Imaging (MRI) of the human central nervous system (CNS). MRI can visualize the anatomy of the body and is used to detect medical conditions. Diagnostic drugs like gadobutrol and gadoterate contain an element called gadolinium that is applied to improve the analysability of MRI-images. The purpose of this study was to examine if contrast-enhanced MRI using a reduced dose of the gadolinium-based contrast agent gadobutrol delivers images of similar quality to those obtained when a full dose of the gadolinium-based contrast agent gadoterate was used. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for gadobutrol
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00375830 ↗ | Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases | Completed | Stanford University | Phase 2 | 2006-01-01 | This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer. |
| NCT00395460 ↗ | Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients | Completed | Bayer | Phase 3 | 2006-09-01 | The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of brain or spine diseases in patients of Chinese origin. |
| NCT00395733 ↗ | Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients | Completed | Bayer | Phase 3 | 2006-10-01 | The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of vascular diseases in patients of Chinese origin. |
| NCT00522951 ↗ | SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study | Completed | Bayer | Phase 3 | 2007-08-01 | This study is conducted to compare the contrast effect and safety of SH L562BB with ProHance, which has already been approved as a pharmaceutical product of similar indication. |
| NCT00623467 ↗ | Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging | Completed | Bayer | Phase 3 | 2007-12-01 | This is a study involving the use of Magnetic Resonance Imaging (MRI) contrast agents called Gadavist. The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Gadavist when used for taking images of the brain and spine. The results of the MRI will be compared to the results of images taken without Gadavist. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for gadobutrol
Condition Name
Clinical Trial Locations for gadobutrol
Trials by Country
Clinical Trial Progress for gadobutrol
Clinical Trial Phase
Clinical Trial Sponsors for gadobutrol
Sponsor Name
